Latest news
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease - Business WireBusiness Wire · Mon, 03 Aug 2026 11:00:00 GMTRocket Pharmaceuticals Provides Positive Clinical Safety Update from Initial Three Patients Treated with Rp-A501 Under Modified Phase 2 Protocol for Danon Disease - marketscreener.commarketscreener.com · Mon, 03 Aug 2026 11:00:00 GMT